Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $2
Akebia (AKBA) Q3 2026 Earnings Call Transcript
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4
Akebia Therapeutics Inc (AKBA) (Q3 2026) Earnings Call Highlights: Vafseo Demand Outpaces ...
BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3
Akebia Therapeutics, Inc. (AKBA) Q3 2026 Earnings Call Transcript
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics: Q3 Earnings Snapshot
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
Akebia Therapeutics Q3 2026 Earnings Call Transcript
Akebia Therapeutics Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $36.900M Miss $46.941M Estimate
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.